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Summary
More often known as the “morning after” pill, the Emergency Contraceptive Pill (ECP) has been used for
over 30 years throughout the world as a method for preventing unwanted pregnancy. EC is a unique
contraceptive preventing unwanted pregnancy after unprotected or poorly protected sexual intercourse.
Access to EC is an important part of overall family planning (FP) strategies, especially in contexts
where the magnitude of unwanted pregnancies, violence, sexual abuse, and their consequences (unsafe
abortions, infanticide) is high. The issue calls for greater attention by national stakeholders.
In Senegal, initiatives for mainstreaming EC in the FP program are fairly recent. EC was included in
Senegal’s FP program in the mid 2000s, and by 2007-2008 it was included in the FP program’s policies
and guidelines. Service statistics indicate, however, that ECP distribution through the public sector is
very low (<2%). While most users access ECPs through the private sector, the volume of sales is not
clear, due to the absence of an operational information system of EC distribution through pharmacies.
In an effort to strengthen EC provision in Senegal and reposition EC within the FP program, Population
Council conducted a study in collaboration with the Reproductive Health Division (RHD) of the Ministry
of Health, Senegal to document the positions and perceptions of Key Opinion Leaders (KOLs) who
can shape the policy and program framework ; as well as documenting providers’ attitudes, beliefs,
and practices regarding EC. Support for this study was provided by the International Consortium for
Emergency Contraception, as part of a three-country project also including Nigeria and India.

Study Objectives
Global objective
The study’s overall objective is collecting information from KOLs and providers about their EC
knowledge, attitudes, and practices, and understanding their options and perceptions that may influence
EC policies and programs.
Specific objectives
• Documenting providers’ EC attitudes, beliefs, and practices, including the issue of repeat use ;
• Capturing KOL’s views and perceptions about EC policy and program issues ;
• Collecting suggestions and recommendations for establishing appropriate interventions for
repositioning EC in public and private health sectors.

Methodology
Study sites
The study was conducted in August and September 2011 in Dakar and Thiès urban areas targeted by the
“Urban Reproductive Health Initiative in Senegal” (ISSU) project, funded by the Bill and Melinda Gates
Foundation.
Respondents
The study collected information from two types of respondents: KOLs and EC providers, with 34
KOLs and 155 providers interviewed. Targeted KOLs included public authorities, parliament members,
professional association members, development partners, NGO representatives, religious leaders,
pharmaceutical distributors, leaders of community-based organizations, and private practitioners.
Providers included a wide range of cadres and included those currently providing, or have provided, EC,
both in the public and private sectors, including doctors, midwives, nurses/ nurse assistants, pharmacists,
and pharmacy counter staff, working in a number of settings: public facilities, private clinics, NGO
facilities, pharmacies, adolescent counseling centers, and school infirmaries.

www.popcouncil.org

v

Primary Results
Provider survey
A considerable proportion of providers (38%) have not received any EC training. Among those trained,
about half were trained as part of on-the-job training. Nearly a third of providers were never trained
in FP counseling, and nearly four out of 10 providers have never received specific training on EC
provision. Staff in private pharmacies, especially counter staff, tends to be less trained.
Providers have some ECP knowledge, but it can be strengthened. For example, improvements in
knowledge about ECP’s mode of action, its timing of use, and eligibility criteria can be strengthened.
Although many providers think ECP is a safe product, negative views persist.
•

•
•

•

While 72 percent of providers indicate ECPs can be provided to all women, irrespective of age
or marital status, when questioned in-depth, responses are lower. Less than half of providers
(43%) responded that all married women could receive ECPs, and the proportion drops for
youth and adolescent girls (37%) ;
Forty-one percent of trained providers were comfortable with ECPs sold without prescription,
while the majority preferred tighter controls ;
Most providers preferred EC provision limited to conventional health facilities such as hospitals,
health centers, private clinics, and pharmacies: They do not favor extending EC at community
and school levels through other supply means ;
Opinions are mixed on EC use by married women, unmarried adolescents, and sex workers.

Analysis of providers’ ECP perceptions indicates:
•
•
•
•

•

Providers believe primary users of EC are aged 15 to 29 years, particularly between 20 and 29 ;
Providers do not favor regular EC use ;
Providers feel EC users, more than others, are at greater risk of acquiring STIs, have multiple
sexual partners, and not use regular contraception ;
Over two-thirds of providers indicated providing instructions on ECP use, and nearly twofifths reported answering client questions, but fewer providers referred clients to regular FP
services (28%) or provided information that ECPs do not protect against HIV and STIs ;
Norlevo® is the commonly prescribed ECP.

Key opinion leader survey
Product beliefs:
•

•
•
•

•
•
•
•

vi

Apart from KOLs directly involved in the managing the reproductive health program, others,
such as parliamentarians and other community leaders, are not as knowledgeable about EC.
Different brands of EC products are not known to KOLs, who stressed the need for informing
communities about this product.
Few KOLs are informed about ECP’s mode of action ;
Many KOLs indicated that EC is legal, available in the national program, and sold in private
pharmacies ;
Some KOLs cited low availability of EC products, particularly in public health facilities, which
have experienced stock shortages since 2010 due to the expiration of the public sector ECP
product, Pregnon® ;
The vast majority of KOLs have also raised EC’s high cost in private pharmacies, which remain
first sources of supply for EC users ;
Legislation should be revised similarly to other contraceptive products: EC products are among
Table A products, therefore requiring a prescription from a doctor or a midwife ;
Although KOLs do not have specific information on EC guidelines and protocols, most are in
favor of integrating EC in the national guidelines for FP service provision ;
Few KOLs are aware of EC studies in Senegal and their findings.

www.popcouncil.org

Attitudes, opinions and perceptions relating to EC use:
•

•

•

•

•

Most KOLs think ECPs are useful, especially among young people, because they help prevent
unwanted pregnancies after unprotected sex, also in cases of rapes and incest, as they can avoid
health and social consequences such as induced abortion and infanticide ;
KOLs indicated perceived reluctance among providers about offering EC services. A public
official stated, “Among providers, there are still some stereotypes. They have not quite accepted this method.
They are concerned about potential overuse. Providers are directing users towards other methods such as injections
and implants ;”
KOLs do not share uniform views of preferred users of EC. For some KOLs, “EC should be
limited to certain women: those with high-risk pregnancies, women victims of rape and sexual assault, sex
workers and women having casual sex (e.g. migrants’ wives, teenagers)”. Others indicated “EC should be
available to all women who need it and as long as there is no medical contra-indication for the method ;”
KOLs urged caution in expanding EC access to the community level. A Ministry of Health
official said, “For extension to the health posts, there are no problems. But for health huts (i.e. facilities lower
than health posts), I suggest we wait for the results of the initial experience to be well established, because even
health workers at this level may overuse it ;”
KOLs believe repeat use of EC is a reality, seen especially in pharmacies. They also believe,
however, that repeat use can also increase risk of STI exposure and substitute for regular
contraception.

Recommendations
This study’s primary recommendations include:
•
•
•
•
•
•

Informing communities for wider product knowledge ;
Training providers ;
Establishing a logistics management system ensuring product availability ;
Improving product affordability ;
Developing effective partnerships, especially with pharmacists ;
Increasing advocacy with decision makers.

www.popcouncil.org
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Introduction
More commonly known as the “morning after pill,” the Emergency Contraceptive Pill (EC) has been
used for over 30 years throughout the world as a method for preventing unwanted pregnancy. EC is a
unique contraceptive that prevents unwanted pregnancy after unprotected or poorly protected sexual
intercourse. It is the only contraceptive method available that can be used immediately after unprotected
sexual intercourse has occurred. Because it is very different from a scope of contraceptive methods, and
because it efficiently prevents pregnancies for those families that use it, access to EC is an important
part of overall family planning (FP) strategies, especially in contexts where the magnitude of unwanted
pregnancies, violence, sexual abuse, and their consequences (e.g. unsafe abortions and infanticide) is
high. The issue demands not only the attention but also the responsibility of public authorities and
stakeholders.
Unfortunately, there is widespread ignorance in regards to this product, especially about its mechanism
of action and the effect EC has on procreation. High priority must be given, on the level of reproductive
health programs in general and of Family Planning (FP) programs in particular, to the diffusion of
accurate information on EC.
In Senegal, initiatives for promoting EC are recent. The first initiative was sponsored by Equilibres et
Population1, a partner of the ECafrique network2, through a pilot introduction of EC in ASBEF facilities
from 2003-2005. Financed by the Compton Foundation3, this project was conducted in partnership
with HRA PHARMA4. The goal was to introduce EC as a way to prevent unwanted pregnancies and
unsafe abortions, and especially as a way to gear women towards regular contraceptive use. Activities
focused on advocacy, the IEC, training providers, and the provision of EC services. This pilot project
demonstrated that the usefulness of EC was well received by the public and that providers, once trained,
found the product easy to administer. In 2005, ECafrique, in collaboration with Equilibres et Population,
launched a sub-regional initiative on EC to strengthen lessons learned from the pilot intervention. This
sub-regional initiative has engaged the Senegalese Ministry of Health and Prevention in implementing
training activities and IEC advocacy in favor of EC. With support from Population Council, several
studies have been conducted. The first study, “EC: A Glance at the Issue in Senegal” (2005), demonstrated
the lack of public knowledge about EC. The second study, done in 2006, was diagnostic. It showed the
need to reinforce information on EC to providers and the community. In 2006, the strategic evaluation
of the national FP program revealed that providers as well as clients had limited knowledge of EC. This
assessment also showed that the provision of EC services was limited to a few health centers and that
the large majority of providers had no specific EC training. These conclusions were corroborated by the
Study of Situational Analysis (AS) of the reproductive health services that was conducted in 2007, which
showed that only 10% of Service Delivery Points (SDP) had dedicated EC products and that 37% of
providers interviewed were not trained in EC.
In 2008, in collaboration with the CEFOREP, a study on unwanted pregnancy prevention in schools in
the area of Pikine-Guédiawaye identified providers’ training, youth awareness, and improvement of the
availability and access to EC products as key actions to be undertaken in the context of EC promotion.
The conclusions of these studies contributed to the integration of EC in policies and reproductive
health service norms. Already in 1998, EC was introduced into the curriculum for provider training. In
2000, EC was mentioned for the first time in the Policies, Norms, and Protocols (PNP). These PNP
mentioned that Combined Oral Contraceptives, progestin pills, and IUDs could be used as part of EC.
In 2005, Pregnon was introduced as the first dedicated EC method in the PNP.
Between 2006-2010, through Population Council’s support, the Ministry of Health was able to train
almost 1,200 providers, pharmacists and pharmacists’ assistants, and health agents on EC provision and
on how to educate clients about the use of this product. Teaching materials were developed and distributed
to providers and health workers in several regions. With the support of UNFPA, the introduction of
Pregnon in public sector SDPs enhanced accessibility to EC in the national health system. In the private
sector, PRODIPHARMA has provided the distribution of Norlevo since 2005.
1 Equilibres et Population is an NGO based in Paris that was founded in 1993 by doctors and journalists to promote the proper use of public aid for development.
2 The African Forum on Emergency Contraception or ECafrique is a network of professionals involved in the field of health that aims to increase the availability of quality EC services in
Africa. This network was created in 2002 and is sponsored by Population Council, an American NGO based in New York.
3 The Compton Foundation is a nonprofit organization based in California, USA, which aims to ensure human and environmental security and preserves the rights of future generations.
4 HRA PHARMA is an institution whose objective is to develop and commercialize medicine or medical devices that meet real needs in health without raising the interests of pharmaceutical companies. It developed Norlevo, which is an EC product.
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In 2009, the study conducted in private pharmacies revealed that they were still the main source of EC
provision and highlighted the need to harmonize EC provision procedure in the private sector. This
study also showed the need to keep pharmacists and their assistants up to date on new EC provision
protocols.
In 2010, the Reproductive Health Division, with support from Population Council, performed an
assessment of the EC integration process into the national health system through a national forum on
EC. This forum revealed that there was a real promotional problem regarding EC in the national health
system despite the efforts made.
Indeed, the following was noted:
•
•
•
•

A widespread lack of public awareness about the product;
Persistent rumors about EC due to the specificity and sensitive nature of the product;
Low inclusion of EC in routine service delivery, especially during initial counseling and FP/
IEC awareness campaigns;
Although private pharmacies are the main supply source for EC users, service providers at
pharmacies need to be updated as to new EC provision protocols.

EC use in the public system remains very low if one refers to routine statistics (<2%). In the private
sector, because of the lack of a functioning information system, the actual use of EC in pharmacies is
not known.
EC service delivery in the public sector continues to be hampered by insufficient promotion of the
product. The beliefs, attitudes, and practices of the general population, and of providers in particular,
will impede the promotion and use of this product with the groups who need it the most.
Thus, in the context of repositioning EC in FP programs, Population Council has conducted a study
of the attitudes, beliefs, and practices of Key Opinion Leaders (KOLs) and providers around EC in
collaboration with the Division of Reproductive Health (DRH).
This study is part of a multi-country study that also includes Nigeria and India. These three countries
receive funding from the Bill & Melinda Gates Foundation in support of the implementation of Urban
Health Initiative underway in these countries.

Goal of the Study
The goal of this study is to propose innovative strategies to reposition EC in the public and private
health sectors.

Study Objectives
Main objective
The study’s overall objective is to collect information from opinion leaders and providers about their EC
knowledge, attitudes, and practices and to understand the options and perceptions that may influence
EC policy and programs.
Specific objectives
• To document providers’ EC attitudes, beliefs and practices, including the issue of repeated use;
• To capture KOLs’ views and perceptions about EC policy and program issues;
• To collect suggestions and recommendations for establishing appropriate interventions for the
repositioning of EC in public and private health sectors.

Methodology
Study sites
• The study was conducted in August and September 2011 in urban areas in Dakar and Thiès
targeted by the “Urban Reproductive Health Initiative in Senegal” (ISSU) project, funded by
the Bill & Melinda Gates Foundation. The choice of sites provides a good opportunity to
collaborate with ISSU.
www.popcouncil.org
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The choice of the cities of Dakar, Thiès, and Mbour is justified by:
•
•

•

Dakar: the choice of Dakar is justified because it is the largest population center in the country
and because it represents many of the social and economic problems of the country in general.
Thiès: Thiès was chosen because it is the second urban center at the national level and because
it is important to have an EC supply available outside of Dakar. Thiès also houses a regional
hospital and several private clinics.
Mbour: Mbour was included as an emerging urban center with an economic and social profile
that differs from the two other choices. Mbour is characterized by its touristic profile, which
exposes adolescents and youth to crucial problems linked to premature sexuality and its
consequences (e.g. unwanted pregnancies).

Study target
The study targeted two types of respondents:
•

•

Key Opinion Leaders (KOL) : this target includes public authorities (officials from the Ministries
of Health, National Education, Youth, and Gender, etc.), members of parliament, members
of professional associations (Order of Pharmacists, Order of Doctors, midwives and
women lawyers associations), representatives of development partners, local NGO members,
professional and religious networks (Journalists and Islamic networks, Siggil Jiggen network),
pharmaceutical distributors, and members of community-based organizations (CBO), especially
women’s, youth, and private sector practitioner associations. The choice of KOLs is justified by
the fact that they play a major role in defining national policies and strategies and in resource
allotment; the population listens to them and they can influence opinions. Their decisions
matter so it is important to understand better their opinions and suggestions in order to build
solid advocacy for EC repositioning.
Service providers: the provider survey targeted a wide range of providers involved in FP service
provision in the public, private, and semi-public sectors. These include doctors, midwives,
nurses/nurses assistants, pharmacists and counter staff, providers involved in adolescent
counseling centers, private clinics and NGO clinics, and school infirmaries.

Selection of sample population
Key opinion leaders: the selection of KOLs was made after systematic decision-making; KOLs were chosen
based on the interest and involvement of their institutions with regards to EC and on the role and
influence that these institutions could have on EC repositioning.
Providers: at the first level, the selection was made based on Service Delivery Points (SDP) that usually
provide FP services, including EC. The choice of SDPs took into account the representation of types
of SDPs (public/private/semi-public) and the level of attendance of the SDP by the population. These
SDPs included public sector facilities (hospitals, health centers, and health posts), semi-public facilities
(COUD Social Center, Dakar Dem Dikk, Social Security Office), private clinics and pharmacies, NGO
clinics (ASBEF, ACDEV), and adolescent counseling centers. At the second level, providers who have,
in the past, offered an EC method and those who continue to do so were included in the study and
interviewed after having giving their consent. At least one provider per SDP was interviewed.
Data collection tools and issues explored
Key opinion leaders: a semi-structured interview guide was administered to each KOL. The issues explored
focused on product knowledge (its legal status, its mechanism of action, its efficacy, and its timing of
use); EC service delivery; EC policies, norms, and protocols; EC research; EC perceptions, attitudes, and
practices; barriers linked to delivery and access; EC use; and suggestions for EC promotion. Interviews
were conducted by the study coordinator with support from a sociologist.
Providers: an individual quantitative questionnaire was administered to providers. As with interviews with
the KOLs, questions focused on product knowledge; EC perceptions, attitudes, and practices; EC use;
and their experience with EC provision. Interviews were conducted by DHR coordinators who were
previously trained in questionnaire administration.

3
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Ethical considerations
For both KOLs and service providers, an informed consent form was given before the beginning of
the interview. Participation in the survey was voluntary and no compensation was given to participants.
Interviews respected the privacy and the anonymity of the interviewees throughout the survey and data
processing through the use of codes for all personal information related to participants. No name was
recorded.
Data management and analysis
The provider survey: data entry was done with Epidata software; the data was transferred to SPSS for
analysis. Univariant and bivariant analyses were performed.
The KOL survey: content analysis was used for qualitative information processing gathered from the
KOLs. This analysis was done along similar themes to allow for comparison between the three countries
covered by the study.

Assessment of Data Collection
Key Opinion Leaders (KOL)
Table 1 shows KOL distribution by profile. A total of 34 KOLs were interviewed, of which 11 are
involved in public institutions (officials from the Ministries of Health, Education, Justice, Youth,
members of parliament, etc.), five are members of professional and religious associations (Women
lawyers and Islamic associations, etc.), four are representatives of development partners, and the rest are
representatives of institutions involved in EC distribution (National Supply Pharmacy, head of logistics
at the DRH, PRODIPHARM), members of Community based organizations (CBO) (such as Synergie
Banlieue and Youth Action Movement), and private practitioners. The wide choice of different targeted
institutions in this study responded to the need for a diversified picture of officials’ opinions (public
policy, civil society, community and NGO decision makers). These officials are likely play a role in
determining policy and program choices for EC repositioning.
Table 1: Distribution of KOL by profile
KOL profile
Policy and program decision makers
Professional association members
NGO members
Development partners
Practitioners
Distributors
Community based organization members
Total

Number
11
5
3
4
1
3
7
34

Source: : KOL survey, July 2011

Providers
The provider survey covered a wide range of SDPs including public, private, and semi-public health
sanitary facilities. 109 SDPs were visited, of which 36 were pharmacies, 26 were health posts, 13 were
private clinics, and 15 were health centers. The sampling also included specific facilities such as counseling
centers for adolescents (4) and school infirmaries, which are specifically designed for adolescents/youth
in school settings (2). Most of the SDPs are concentrated in Dakar (82% of SDPs).
Table 2: Distribution of Service Delivery Points by type
Type of facilities visited
Hospital
FP reference center
Health center
Health post
Adolescent Counseling Center
Private clinic
NGO clinic
Pharmacy/ Private pharmacy
EPS 1
CMS
Total
Source: provider survey, September 2011

Dakar
1
14
20
3
10
2
30
3
2
89

Thiès
4

Mbour
1

4
2

1
2
1
1

4
1

2
1

12

8

Total
5
1
15
26
4
13
2
36
5
2
109

At the 109 SDPs visited, 155 providers were interviewed. Midwives represented the majority of the
sampling (54%); the strong presence of midwives in the sampling is explained by the fact that they are
the first line providers in FP service delivery. Counter staff in pharmacies made up 19% followed by
www.popcouncil.org
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pharmacists (17%) and doctors (6%). The other categories had little representation in the sampling.
Table 3: Distribution of providers by professional category
Type of provider
Midwife
Pharmacist
Doctor
Counter staff
Other
Total

Dakar
68
21
8
28
4
129

Source: provider survey, September 2011

Thiès
10
3
1
2

Mbour
5
2
1

Total
83
26
10
30
6
155

2
10

16

Women made up a majority of the provider sampling (71.6%). In Mbour, the number of men was higher
(40%) compared to Thiès and Dakar (27.9% and 25% respectively).
Table 4: Distribution of providers by gender
Gender
Male
Female
Total

Source: provider survey, September 2011

N
36
93
129

Dakar

%
27.9
72.1
100

N
4
12
16

Thiès

%
25
75
100

N
4
6
10

Mbour

%
40
60
100

N
44
111
155

Total

%
28.4
71.6
100

The average age of providers was 43.5 years with a minimum age of 25 and a maximum of 70. The average
months of EC experience was 59.4 months, or almost 5 years, which corresponds to the introduction
of training activities for providers within the national FP program that began in 2005. However, Table 5
indicates that certain providers have experience (22 years) previous to the initiative to introduce EC into
the national health system, which dates to 10 years ago with the introduction of Pregnon and Norlevo in
the public and private sectors. These providers were most likely using traditional contraceptive pills and
perhaps IUDs, which were methods previously used for FP.
Table 5: Distribution of providers by age and EC experience
Dakar
Provider age (years)
N
129
Average
44
Minimum
25
Maximum
70
Number of months of EC experience
N
111
Average
58
Minimum
0
Maximum
264

Thiès

Mbour

Total

16
43
29
59

10
44
31
56

155
44
25
70

15
45
1
120

10
102
36
150

136
59
0
264

Table 6 shows the quasi-effectiveness of EC provision. Amongst the 155 providers who have provided
EC in the past, 92% continue to do so. However, 11 out of 83 midwives who have provided EC in the
past no longer do.
Table 6: Percentage of providers currently offering EC by professional category and region
Dakar
Thiès
Mbour
Professional category
N
%
N
%
N
%
Midwife
58
85.3
9
90.0
5
100
Pharmacist
21
100
3
100
2
100
Doctor
8
100
1
100
1
100
Counter staff
27
96.4
2
100
Other
4
100
2
100
Total
118
91.5
15
93.8
10
100

N
72
26
10
29
6
143

Total

%
86.7
100
100
96.7
100
92.3

Key Opinion Leaders (KOL): Who are they?
The choice of KOLs was motivated by the major role that they play in the influencing the ideas and
opinions of community and especially for their role in decision-making at the social, political, and
economic levels. Indeed, KOLs play a key role in the definition of policies and national strategies. They
fix national priorities, especially the allotment of resources. Their decisions matter so it is important to
understand better their opinions and perceptions on major social interest topics such as family planning
and emergency contraception.
The involvement of KOLs in EC repositioning strategies is justified by the fact that they are potential key
supporters or critics of EC. KOL integration in programs remains a fundamental issue for EC advocacy.
In the context of this study, a wide range of KOLs was targeted from policy makers/program managers,
members of professional associations/networks, members of local NGOs, development partners, CBO
representatives, distributors, and private practitioners.
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Table 7: List of visited institutions
INSTITUTIONS
Public policy makers:
•
Ministry of Health and Prevention (DRH)
•
Ministry of National Education
•
Ministry of Youth
•
National Assembly
Development partners:
•
WHO
•
UNFPA
•
USAID
•
Marie Stopes International (MSI)
Professional associations:
•
Order of Senegalese doctors
•
Order of Senegalese pharmacists
•
National Association of Senegalese Midwives
Networks:
•
Islamic and Population networks (Religious)
•
Health journalists and Population networks

INSTITUTIONS
Local NGOs:
•
ASBEF
•
Action for Development (ACDEV)
Practitioners:
•
A private doctor

CBOs:
•
Siggil Jiggen network
•
Forum for African Women Educationalist
•
Movement for Youth Action
•
Synergie Banlieue
Distributors:
•
PRODIPHARM
•
National Supply Pharmacy
•
ADEMAS
Police:
•
The Camp Pénal Women’s Prison5

5

Product Knowledge
General Product Information
Besides the KOLs who are directly involved in the management of routine reproductive health programs
(especially leaders in the Ministry of Health, Ministry of National Education, development partners, and
local NGO members), the majority of KOLs do not possess accurate information on EC. They know it
by the name of “the morning after pill,” but they cannot name different EC brands available in the country,
nor can they discuss its mechanism of action or its side effects. This is the case with members of
parliament, journalists, religious leaders, and certain members of CBOs. Thus it is important to increase
EC knowledge amongst these KOLs by giving them more specific product information. Furthermore, it
is important to raise awareness about product safety. This could also push leaders to adhere to policies
that promote EC.
The best-known EC products
According to KOLs, the main EC products available are the following:
•
•

•
•
•
•

Norlevo® (1.5 mg), which was made available by the DRH before 2006, but it is currently only
available in private pharmacies;
Pregnon®, which was introduced in the public system by the national FP program since May
2006 thanks to a UNFPA donation. However, the available stock expired in September 2010
due to lack of promotion and distribution by public sector providers;
DUET, which is the new product that will replace Pregnon®;
Optinor, which is only available in ASBEF facilities;
Conventional contraceptives pills (Loféménal, Microval, ovrette, etc.);
IUDs.

EC legal status
The vast majority of KOLs believe that EC products are legal based on the fact they are available in the
FP national program alongside other contraceptive products and are sold in private pharmacies. Speaking
of Norlevo®, a member of a professional association stated: “It is a licensed product. […] As for other products
found in private pharmacies, it received the visa from Pharmacy and Laboratory Administration” (a member of a
professional association). However, according to some KOLs, although EC products are licensed, the
pharmaceutical regulation of contraceptives in general and EC in particular should be reviewed. One
member of a professional association stated: “Norlevo® figures on the list of Table A drugs and should be sold
5 The Camp Pénal Women’s Prison was not visited for administrative procedural reasons.
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upon presentation of a prescription, but in reality, it is given upon demand” (a member of a distributors network).
According to these KOLs, this situation should be fixed because now, because “according to regulations, only
doctors and midwives are allowed to prescribe this method; however, in practice, it has been noted that nurses provide this
product. […] It is important therefore to eliminate some of these contradictions” (a distributor).
Product usefulness
All KOLs are unanimous on the usefulness of the product and believe that the product should be
popularized for several reasons:
•
•
•
•
•
•

“So that everyone will have the information”;
“It is an efficient product to prevent unwanted pregnancies as well as cases of death and some social situations
(e.g. infanticide, abandonment, clandestine abortions and their social consequences)”;
“It is a useful product that has its place in the system to respond to unmeet needs”;
“It can help young people better manage their futures”;
“It is easy to use”;
“For different reasons, there are women who do not use a regular method of contraception”.

Some KOLs justify the usefulness of the product based on the fact that “it can help fight girls’ high dropout
rate from school and it can help certain organizations fight against sexual violence by taking better care of victims of abuse
or sexual violence” (a member of a professional organization).
Although for the popularization of this product, some KOLs reveal their fears and believe that its use
should be supervised because “it should not be used as the one and only method” (a decision maker).
Some reservations on the part of KOLs are for personal reasons: “Personally, as a Muslim, mother, and
educator, I think that its use should be limited. Sociocultural values cannot be violated in one fell swoop. With this method,
we must be careful not to offend people. Because of the sensitivity of this subject, religious leaders should be involved. But in
critical situations (e.g. rape and incest), it should be used to help young people, at least on a psychological level” (a decision
maker).
Product efficacy and safety
According to KOLs, EC is considered effective and safe if it is properly taken at the right time as well as
properly conserved. In principle, all providers understand EC insofar as they have been trained. KOLs
justify product efficacy by high demand in private pharmacies and because few failures and complaints
have been reported. Only one member of a CBO mentioned a failure. As for the side effects, the KOLs
do not exclude them, but they are minor. According to some KOLs, “This product is safe due to the fact that
before its introduction, as for any drug, it received approval from the DPL” (member of a professional association).
The KOLs do not exclude the probability of the existence of counterfeit products in the context of the
market, especially in the informal sector, which is very porous because it lacks an efficient monitoring
system. According to KOLs, “As with all drugs, EC products can be objects of counterfeit” (a decision maker).
No KOL reported having seen or heard of the existence of counterfeit products. These KOLs depend
on monitoring results: “All contraceptive products were enrolled in the quality control program and no counterfeit
product was reported” (a program manager).
EC in Policies/Norms and national guidelines
EC has been incorporated in the latest Policies/Norms and Protocol (PNP) documents under Family
Planning/Reproductive Health reviewed in 2007-2008. It also appears prominently in the new version
of PNP that became available in 2012. It must be noted that a majority of KOLs are in favor of EC
integration into the national guidelines as long as “EC is part of a range of contraceptive products available in
the national FP program” (a program manager/decision maker). However, KOLs are not very aware of
these national guidelines.
Supply source/logistics system
Senegal’s EC products are supplied through two systems. In the public sector, supply follows the official
system of contraceptive products and is done with the DRH with support from development partners,
mainly UNFPA, which has supported the DRH in the establishment of these products (Pregnon®)
since 2006. In the first stage, the DRH directly dispatches the products to the medical regions. Districts,
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where activities are implemented operationally, get their supply from their medical regions. Since 2010,
through an agreement signed between the DRH and the Central Medical Stores (CMS), the latter does
DRH’s purchasing and ensures supply and distribution according to the division’s recommendations,
including donated products. A rates system for contraceptive products including EC was validated by
the Ministry of Health, who fixed and published the official prices for contraceptive products at all levels
of the health system. The lack of contraceptive consumer data through the Quarterly Stock Registers
(RTS) is a weak link in the supply system, as real consumption is not known, which in turn limits the
quality of product orders. Since 2010, the system has witnessed product shortage due to the expiration
of Pregnon6® because of a lack of promotion on the part of providers. Currently, a new product named
DUET has replaced Pregnon® in the public system. DUET was commissioned by the CMS in the
context of the agreement, but the quantities available did not cover the country’s annual needs. Qualified
personnel at all public facilities, except at health huts, ensure EC provisions. Generally, gynecologists and
midwives provide the product.
In the private sector, EC is sold in private pharmacies under the brand name Norlevo®. In private clinics,
doctors and midwives generally provide EC through a prescription that the client can then fill at a private
pharmacy. Norlevo® is sold to customers at 3,275 FCFA. Five main wholesalers share this private market:
PRODIPHARM, LABOREX, SODIPHARM, COPHASE, and BIOPHRAM. According to estimates,
“almost 80,000 units of Norlevo® are consumed in private pharmacies. […] The Dakar region represents almost 60%
of the national market. […] The product is especially used in cities” (a distributor).
At ASBEF, “Optinor® is available thanks to support from the IPPF. It is sold at 2,000 FCFA” (an NGO employee).
EC research
Few KOLs were informed about the existence of EC studies done in Senegal and their conclusions. The
principal studies that were cited by KOLs were:
•
•
•
•

“EC: A Glance at the Issue in Senegal” (Population Council 2005);
“Diagnostic Study on EC” (CEFOREP/2006);
“Study on the Prevention of Unwanted Pregnancies in Schools in the Pikine-Guédiawaye Region” (Population
Council et CEFOREP 2007);
“Study on EC in Private Pharmacies” (Population Council 2009).

Some KOLs expressed interest in certain research concerns:
•
•
•
•
•
•
•
•
•

EC acceptability by the population and by decision makers;
Stigmatization of EC users;
Religious aspects linked to EC use;
Efficacy and safety of the product;
Perception of parents and of the community of EC use by adolescents/unmarried youth;
Effects of repeated use/abuse;
EC use and exposure to HIV/AIDS;
KAP survey among youth;
KAP survey among providers.

KOL EC Attitudes, Opinions, and Perceptions
Product acceptability
Overall, KOLs have a high opinion of EC. They think that it has a place in the range of contraceptives
and may provide a remedy in certain circumstances (e.g. forgotten pill, rape, incest, etc.). According to
some, “It should be promoted even amongst young single people because it prevents unwanted pregnancies (especially in
the case of neglecting to take the pill, rape, and incest) and their social consequences (e.g. induced abortion, infanticide)”
(***author).
This is confirmed by the comments of some KOLs:
6 Almost 25,000 units of Pregnon expired due to failure of providers to deliver the product. This shortage reflects the dysfunctional supply and management system of contraception products
noted in 2011
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“This is a method that we need in the context of our activities because unwanted pregnancies can have very serious social
consequences (for example, women imprisoned for infanticide)” (member of a professional association).
“For young people who are not married, I am not against it. The evidence shows that today sexual intercourse is trivialized
even though we are in a Muslim country. It would be hypocritical to remain silent. […] I would prefer that they use EC
than commit infanticide” (NGO member).
EC can contribute to FP repositioning
“We are in advocacy. We must help people correct certain errors. Thus, it must be known and accepted by the whole
population, and not be limited to only one target (youth)” (program manager).
However, some believe that distribution should be accompanied with advice for the following reasons:
•

•
•

Better targeting of men since EC is a product destined specifically for women but is not known
to men who might need to buy it for their partners. Indeed, one distributor stated that “70 to
80% of those who buy it are men. It is a product destined for women but bought by men. They are relatively
young and they know the price” (distributor).
Inform EC users that this is an exceptional method that cannot replace regular contraception
because “young people seem to use it as regular contraception” (program manager).
Inform young people that EC does not protect against STIs because “EC users are more prone to
sexual libertinism and to not protecting themselves against STIs and HIV” (NGO member).

The KOLs put forward some reservations about EC use, especially promiscuity, abuse, replacement of
regular FP methods, religious considerations, and lack of protection against STIs/HIV/AIDS.
According to one KOL: “It should be popularized, but we should first promote condoms to protect against STIs/HIV.
It is a back up method that does not protect against AIDS” (members of professional associations).
Perceptions of provider attitudes toward the product and its acceptability
According to some KOLs, providers still feel some reluctance despite training. This would often be
linked to personal issues.
“There are some limitations with providers. Midwives are a bit blocked; they make the connection with abortion. Perhaps
there is also a link with the target (young people)” (development partner).
“With providers of a certain age bracket, there could also be a problem because they envision their daughters in front of
them. Their reactions sometimes go beyond the work setting” (NGO representative).
“For providers, there are still some stereotypes. They have not yet fully accepted this method. […] They are concerned with
overuse. And we find that counseling is now very biased towards injections and implants” (public authority).
EC provision
The opinions of KOLs remain divided as to who should receive EC:
For some: “EC must be limited to certain categories of women: those with an at risk pregnancy, victims of rape or sexual
assault, prostitutes, and woman who have occasional sex (e.g. wives of emigrants, adolescents)” (member of a CBO).
For others: “EC must be available for all women who need it as long as there is no medical contraindication for the
method” (decision maker).
It is the same in regards to where EC should be made available: some believe that EC services should be
expanded to other types of less conventional sanitary facilities such as sanitary facilities in military camps,
Counseling Centers for Adolescents (CCA), Medical Infirmaries for Schools (IME), and universities.
Others do not think that EC should be available at the community level: “There is no problem in health posts.
As for the huts, I suggest waiting until the initial experience is firmly established and even health workers at this level may
overuse it” (program manager).
Repeated EC use
The vast majority of KOLs believe that contraceptive use should be exceptional; they define repeated
use as exceeding once a year. The vast majority of KOLs argue that repeated use is a reality that is mostly
seen in private pharmacies. According to pharmacists, repeated use is noted mainly with young people.
However, the lack of reliable statistics does not allow them to confirm this.
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KOLs believe that repeated use can cause problems, especially:
•
•
•

Abuse of product;
Replacement or halt of regular contraception;
Exposure to HIV.

Barriers to EC Provision and Access
EC Access
According to KOLs, the main barriers to EC access are the following:
•
•
•
•
•
•
•
•
•
•
•

Lack of information;
Provider’s attitude (e.g. reception or bias);
Product unavailability;
Shame;
Distance from supply source, mainly the SDP;
High cost of EC products in pharmacies;
Side effects linked to product use;
Stigma especially in areas where social pressure is strong: “When someone asks for this product, you
say to yourself that he has done something or has the intention of doing something” (decision maker);
Religious convictions;
Husband’s lack of understanding;
Rumors about contraception in general.

Barriers to EC Provision
According to KOLs, the main barriers to EC provision are the following:
•
•
•
•
•
•
•
•

Provider’s lack of training;
Religious convictions;
Product unavailability due to the expiration of the previous stock and the non-renewal of the
stock at SDP7;
The wait time is considered too long by client;
Administrative paperwork faced by clients;
Unsuitable operating hours;
Lack of privacy and anonymity at visits (recording of personal information such as name or
address) at public facilities;
Lack of counseling at pharmacies where client-provider interaction is very low (no space for
counseling).

According to KOLs, the main challenges to EC promotion are the following:
•
•
•
•
•
•
•
•

Access to product information and communication;
Product availability:
Provider training, including pharmacists and counter staff;
Geographic and financial accessibility;
Support from the public and certain providers;
Harmonization of practices on usage times because pharmacists rely on product inserts;
Regulatory review (Table A drug); it would therefore be necessary to declassify this product to
facilitate access;
Quality of service (e.g. good counseling, privacy, anonymity, and lack of stigma).

7 The previous stock of Pregnon acquired through the DRH expired in September 2010, and it was only renewed recently. The amount available does not cover the regions’ annual needs.
The lack of availability of EC products is in a context of overall contraceptive product shortage due to the problem of retaining information, which occurs when the quarterly inventories
required for planning future contraceptive needs are not transmitted
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KOL Recommendations for EC Promotion
According to KOLs, EC promotion should be a multisectoral approach that involves a variety of
stakeholders, namely:
Public authorities (Ministry of Health, Ministry of National Education, Ministry of Justice, Ministry of
the Family, Ministry of Youth, etc.):
•
•
•
•
•
•
•

Community stakeholders (CBO, Peer Educators, Badienu Gox);
Religious leaders;
Parliamentarians;
The media;
Lawyers;
Civil society;
Traditional communicators.

KOLs have made the following recommendations for priority EC intervention:
•
•
•
•
•
•
•

Strengthen information for a wider dissemination of the product;
Train providers;
Ensure proper logistical management to guarantee product availability;
Increase financial accessibility;
Develop partnerships through more involvement of pharmacists;
Develop advocacy with decision makers;
Develop research on product acceptability and safety.

EC Training for Providers
Counseling is an important component of service delivery that guarantees not only the client’s informed
choice but also, as a result, the quality of services offered. The graph below indicates that almost
one third of providers have not had any training in FP counseling. The training deficit is particularly
noticeable with providers in pharmacies: only 13% of counter staff and 42% of pharmacists have
received training in FP counseling. The percentage is 94 amongst midwives. This is due to the fact that
FP training programs have targeted public sector providers; the private sector benefited from few FP
training programs. It is important to better target this sector in order to harmonize FP service delivery
at a national level.
Graph 1: Proportion of providers previously trained in FP counseling by qualification
100%

94
80

80%

67,7

60%
42,3
40%
13,3

20%
0%

Midwife (N=83)

Pharmacist (N=26)

Doctor (N=10)

Counter staff (N=30)

All (N=155)

Table 8 shows that EC training is not very integrated in the initial training for providers. Only 22.6% of providers
received EC training during their basic training. Indeed, EC integration in the provider-training curriculum
is very recent. 51.6% of them received it while on the job. It can be noted that 38.1% of providers have
never had any specific EC training, nearly four providers in ten. Dakar has the highest rate of providers
who have never received specific EC training (39.5%).
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Table 8: Percentage of providers with EC training

Dakar
(N=129)
N
%
26
20.2
65
50.4
51
39.5
18
14

Training
Trained specifically in EC during basic training
Trained specifically in EC on the job
Has not received specific training in EC
Trained in EC during the last 12 months

Thiès
(N=16)
N
%
4
25
10
62.5
3
18.8
6
37.5

Mbour
(N=10)
N
%
5
50
5
50
2
20
1
10

Ensemble
(N=155)
N
%
35
22.6
80
51.6
56
36.1
25
16.1

Only 16.1% received specific EC training in the 12 months preceding the survey.
Table 9: Percentage of providers with EC training by professional category
Dakar
Thiès
Professional Category
N
%
N
%
Midwife
51
75
7
70
Pharmacist
12
57.1
3
100
Doctor
5
62.5
1
100
Counter staff
7
25
2
100
Other
3
75
Total
78
60.5
13
81.3

N
3
2
1

Mbour
%
60
100
100

2
8

100
80

N
61
17
7
9
5
99

Total

%
73.5
65.4
70
30
83.3
63.9

63.9% of providers who have already provided EC received specific EC training. The highest percentages
of providers without EC training were found with counter staff (70%) and pharmacists (34.6%).

EC Knowledge
Table 10 shows that there is significant percentage of providers who do not understand EC mechanism
of action: 57.4% quoted the stoppage of ovulation and 63.9% the prevention of egg implantation.
Table 10: Percentage of providers’ understandings of the EC mechanism of
Without Training
%
N
25
44.6
Inhibits ovulation
31
55.4
Impedes implantation
1
1.8
Induces abortion
9
16.1
Kills the spermatozoon
10
17.9
Do not know
6
10.7
Other
11
19.6
The period of use of EC is 120 hours

action
With Training
N
64
68
1
19
7
17
42

%
64.6
68.7
1
19.2
7.1
17.2
42.4

N
89
99
2
28
17
23
53

Total

%
57.4
63.9
1.3
18.1
11
14.8
34.2

There are differences in what trained providers and untrained providers know about the EC mechanism
of action. 44.6% of untrained providers indicated the blocking ovulation as the EC mechanism of
action as opposed to 64.6% of trained providers. Also, few providers are aware of the newest guidelines
related to the timing of EC administration, which is now 120 hours. The highest percentages regarding
this newest guideline were found with doctors and midwives (50% and 41% respectively). On the other
hand, the level of knowledge of pharmacists remained low (11.5%). Differences between trained and
untrained providers persist.
Graph 2 also reveals that a large number of providers do not know that pregnancy is an exclusion
criterion for use. More than half of providers did not cite pregnancy as an EC exclusion criterion8.
Graph 2: Knowledge of medical contraindications of EC use
50
45

44,5

40
35

31

30
25

27,7
18,1

20
15

7,7
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9,7

7,7
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8,4

7,7

5
0

Pregnancy

Heart
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Liver
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Breast-feeding

High blood
pressure

Cancer

Diabetes

Other

No medical
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Do not know

It can be noted that few providers cited cervix cancer as an EC exclusion criterion.
The study results also reveal that knowledge around EC’s mechanism of action remains low amongst
providers. Few of them could give correct answers as to the EC mechanism of action, the time of
use, and the eligibility criteria. It is important to build providers’ knowledge in this area through the
organization of training sessions.
8 Training documents mention that the presence of a pregnancy was a criterion of non-eligibility for EC. Research has shown that EC use does not interfere with the progress of a pregnancy.
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Opinions about EC
It should be noted that few providers equate EC practice with a form of abortion. 11% of them believe
that EC would be a form of abortion.
Table 11: Percentage of providers who think EC is a form of abortion
Dakar
Thiès
Professional category
N
%
N
%
Midwife
4
5.9
Pharmacist
6
28.6
Counter staff
5
17.9
1
50
Total
15
11.6

N

Mbour

2

%

Total

N
4
8
6
15

100

%
4.8
30.8
20
9.7

However, amongst pharmacists, a significant number of counter staff (20%) and pharmacists (30.8%)
equate it with abortion. Moreover, there is still much resistance in regards to the eligibility of all women
for EC use, which is contrary to national guidelines that state that all women are eligible for this method
if there are no medical contraindications.
Graph 3: Distribution of providers by knowledge of EC eligibility criteria
75,8

80
64,3

71,6

Without training (N=56)

Total (N=155)

With training (N=99)
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42,4

42,9 42,4 42,6
40
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0
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7,1

5,8

5,1
Others

All victims of rape

Indeed, the percentage of providers who stated that all women regardless of marital status were eligible
for EC was 75.8% and 64.3% respectively for trained and untrained providers. Less than 45% of
providers believe that married women and adolescents were eligible for EC.
Although a majority of providers believe that EC is a safe product, few of them stated that it should be
sold without a prescription (42.4% and 37.5% respectively for trained and untrained providers).
Graph 4: Distribution of providers by opinions on certain conditions of EC provision
100

78,6

92,9

87,7
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In addition, they are not in favor of providing EC to women in anticipation of unprotected sex.
Graph 5: Distribution of providers by opinions on type of providers authorized to supply EC
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Graph 5 indicates that a vast majority of providers is in favor of EC being provided by qualified medical
personnel (e.g. doctors, midwives, and pharmacists). Most of them are reluctant as to the provision by
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others besides these types of providers. Only 40.6% of providers believe that social workers should
provide EC. Indeed, the percentage of providers in favor of EC being provided by community workers
(e.g. community health agents, and traditional birth attendants) remains very low (less than 20%).
Table 12: Distribution of providers by opinions on where EC should be offered
Ensemble
(N=155)
N
%
148
95.5
152
98.1
147
94.8
51
32.9
126
81.3
122
78.7
13
8.4
6
3.9
92
59.4
11
7.1

Type de PPS
Hôpitaux
Centres de santé
Postes de santé
Cases de santé
Clinique privée
Pharmacie
Ecole
Police
Centre conseil Ado
Autres

These findings are similar regarding where EC should be
offered. Opinions are mostly in favor of conventional medical
facilities (e.g hospitals, health post and centers, private clinics
and pharmacies) as opposed to other non-conventional facilities
such as health huts, school infirmaries, and police. The latter
could enhance access to EC services for vulnerable groups such
as students, rural women, and prisoners. A significant percentage
of providers (41.1%) are not in favor of EC provision in
Adolescent Counseling Centers, which are place specifically
reserved for that target.

Graph 6: Distribution of providers by opinion on when EC should be used
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If a majority of providers are in favor of EC being provided to victims of rape and sexual abuse, and
women who have unprotected sex and want access to EC, opinions are more mixed in regards to EC
use by sex workers, married women, single adolescents, and women living in conflict zones (refugees).

Perceptions of EC
Providers were interviewed about their perceptions of the profile of the average EC user. More than
half of providers indicated that they believe EC users are less than 30 years old. Almost 35% indicated
the age range would be between 20 and 29 years old, 15% between 15 and 19 years old, and 4% at less
than 15 years old. On the other hand, 29% of providers believe that women of all ages would be EC
users. However, a small percentage felt that they would be older than 40.
Table 13: Distribution of providers by opinions on age of EC users
Dakar
Thiès
Ages
N
%
N
Less than 15 years
4
3.1
2
Between 15 and 19 years
20
15.5
4
Between 20 and 29 years
46
35.7
3
Between 30 and 39 years
16
12.4
40 years and older
3
2.3
Women of all ages
34
26.4
6
Other
1
0.8
Do not know
5
3.9
1
Total
129
100
16

%
12.5
25
18.8

Mbour
N
%
5

50

37.5

5

50

6.3
100

10

100

N
6
24
54
16
3
45
1
6
155

Total

%
3.9
15.5
34.8
10.3
1.9
29
0.6
3.9
100

In addition, providers’ opinions on repeated use were discussed. The vast majority believes that EC use
should be limited. Almost 76% believe that it should not exceed four times a year. This includes almost
two providers in ten who state that EC should be used only once a year and almost six providers in ten
believe that EC should be used between two and four times a year. Few providers believe that EC should
be used at each menstrual cycle or any time it is needed (less than two in ten providers).
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Table 14: Distribution of providers by opinions on number of times a woman can use EC per year
Total

N
15
41
1
6
9
1
1
74

Once a year
2-4 times a year
5-10 times a year
Once a month
As often as necessary
Other
Do not know
Total

%
20.3
55.4
1.4
8.1
12.2
1.4
1.4
100

There is a negative perception by providers towards
women who use EC. Almost 70% of them believe
that they run a higher risk of risky sexual behavior,
will have an STI (68%), will have multiple sexual
partners (58%) and will not use regular contraception
(57%).

Table 15: Distribution of providers by perceptions of women who use EC
Without training
N
%
More likely to engage in risky sexual behaviors
41
73.2
More likely to have multiple sexual partners
31
55.4
More likely to have an STI
38
67.9
More likely to not be able to use other contraceptive methods
33
58.9

With training
N
%
N
67
67.7
108
59
59.6
90
67
67.7
105
56
56.6
89

Total
%
69.7
58.1
67.7
57.4

EC Service Delivery
The data in Table 16 show that while the majority of providers inform their clients of the EC mechanism
of action (72%) and how it should be used (67%), and about FP (67%), few of them refer clients to
FP service (28%) or to other DRH services (29%). Almost half (49.7%) inform clients of side effects,
almost one third (32.9%) of providers do not give FP advice.
Table 16: Distribution of providers by services normally provided to EC
N
52
92
104
112
77
104
83
69
43
45
11

Provides only EC pills
Provides general information about EC
Provides instructions on how to take EC
Provides the mode of use of EC
Provides information on the side effects
Provides advice on family planning
Provides information on STIs and HIV
Responds to questions and concerns
Refers to family planning services
Refers to other services
Offers other services to EC clients

Total

%
33.5
59.4
67.1
72.3
49.7
67.1
53.5
44.5
27.7
29
7.1

A vast majority of providers indicated that they normally offer Norlevo® to their clients (almost eight
providers in ten).
Graph 7: Types of EC products normally provided to users
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Besides Norlevo®, Pregnon® is still the most offered product. As the data in Graph 7 indicates, other EC
products remain scarce in routine EC provision.
According to providers, EC products usually available in public facilities were mostly Lo-Femenal (79%),
Ovrette (73%), and IUDs (54%). It can be deduced that EC products, specifically, are not readily available
in public facilities. Pregnon® was only cited by 40% of providers and Norlevo® by only 2% of providers.
It can be deduced that providers also use other options besides Pregnon. In private pharmacies, Norlevo®
is cited (98%). However, other products such as Securil and Microval are available. We note the presence
of a larger variety of EC products in private clinics as the data in Graph 7 shows. This indicates that
there are several options in EC provision. Other products are rare
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Graphs 8-10: Type of products available by type of SDP
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Conclusion
The KOL and provider survey results reveal that EC is an integral part of the national FP program. In
fact, EC ranks high not only in policy documents, norms, and protocols regarding DRH/FP service
delivery, but also in provider training documents. KOLs and providers are conscious of the importance of
EC in the prevention of unwanted pregnancies and are in favor of EC integration in national guidelines.
However, it is evident from these results that there is an urgent need to improve EC accessibility and
the quality of its services. The vast majority of KOLs and providers believe that community awareness
and the popularization of the product should be the primary activities to build awareness amongst the
populations, young people in particular, about the product. The information given to communities could
also contribute to reduce stigma, biases, worries, and reluctance about EC use.
The persistence of these prejudices toward EC could be linked to EC’s recent past in Senegal.
Its official introduction to the national system goes back less than six years. The ideas and experiences are
being built now, and it takes time to change ideas and behavior. EC history in Senegal is highly dependent
on FP history, which is characterized by low use of modern methods and by the weight of sociocultural
pressures. However, the perspective of better acceptance of the product is open. In fact, facing the
scope of sexual violence/abuse, induced abortions, and the question of women’s and adolescent health
rights, there are more and more decision makers and communities who wish to preserve the health
and well being of certain vulnerable groups, particularly adolescents/young people and women. These
factors could provide the momentum needed for EC promotion.
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Recommendations
The primary recommendations of the study are:
•
•
•
•
•
•

Community awareness for wider product knowledge;
Provider training;
Establishment of a logistics management system to ensure product availability;
Improve product affordability;
Development of partnerships, especially through greater involvement of pharmacists;
Development of advocacy activities with decision makers.
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